KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Share-based Compensation (2016 - 2025)

Rigel Pharmaceuticals has reported Share-based Compensation over the past 16 years, most recently at $2.7 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $2.7 million for Q4 2025, up 31.67% from a year ago — trailing twelve months through Dec 2025 was $12.7 million (up 2.57% YoY), and the annual figure for FY2025 was $12.7 million, up 2.57%.
  • Share-based Compensation for Q4 2025 was $2.7 million at Rigel Pharmaceuticals, down from $3.4 million in the prior quarter.
  • Over the last five years, Share-based Compensation for RIGL hit a ceiling of $5.1 million in Q1 2024 and a floor of $1.9 million in Q4 2023.
  • Median Share-based Compensation over the past 5 years was $2.6 million (2021), compared with a mean of $2.8 million.
  • Biggest five-year swings in Share-based Compensation: crashed 52.62% in 2023 and later soared 86.15% in 2024.
  • Rigel Pharmaceuticals' Share-based Compensation stood at $2.3 million in 2021, then surged by 74.43% to $4.1 million in 2022, then crashed by 52.62% to $1.9 million in 2023, then rose by 7.97% to $2.1 million in 2024, then skyrocketed by 31.67% to $2.7 million in 2025.
  • The last three reported values for Share-based Compensation were $2.7 million (Q4 2025), $3.4 million (Q3 2025), and $3.3 million (Q2 2025) per Business Quant data.